These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31516369)

  • 1. Efficacy and safety of
    Aghdam RA; Amoui M; Ghodsirad M; Khoshbakht S; Mofid B; Kaghazchi F; Tavakoli M; Pirayesh E; Ahmadzadehfar H
    World J Nucl Med; 2019; 18(3):258-265. PubMed ID: 31516369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
    Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R
    Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years.
    Assadi M; Rezaei S; Jafari E; Rekabpour SJ; Ravanbod MR; Zohrabi F; Amini A; Keshmiri S; Dadgar H; Ahmadzadehfar H
    World J Nucl Med; 2020; 19(1):15-20. PubMed ID: 32190017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
    Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
    Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a Prospective Phase 2 Pilot Trial of
    Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM
    Clin Genitourin Cancer; 2019 Feb; 17(1):15-22. PubMed ID: 30425003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety Profile and Therapeutic Efficacy of One Cycle of Lu177-PSMA in End-Stage Metastatic Castration-Resistant Prostate Cancer Patients with Low Performance Status.
    Gupta M; Choudhury PS; Rawal S; Karthikeyan G; Talwar V; Dutta KD; Singh A
    Nucl Med Mol Imaging; 2019 Dec; 53(6):423-431. PubMed ID: 31867078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.
    Kratochwil C; Giesel FL; Stefanova M; Benešová M; Bronzel M; Afshar-Oromieh A; Mier W; Eder M; Kopka K; Haberkorn U
    J Nucl Med; 2016 Aug; 57(8):1170-6. PubMed ID: 26985056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.
    Ahmadzadehfar H; Eppard E; Kürpig S; Fimmers R; Yordanova A; Schlenkhoff CD; Gärtner F; Rogenhofer S; Essler M
    Oncotarget; 2016 Mar; 7(11):12477-88. PubMed ID: 26871285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.
    Heck MM; Retz M; D'Alessandria C; Rauscher I; Scheidhauer K; Maurer T; Storz E; Janssen F; Schottelius M; Wester HJ; Gschwend JE; Schwaiger M; Tauber R; Eiber M
    J Urol; 2016 Aug; 196(2):382-91. PubMed ID: 26964917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (
    Tagawa ST; Vallabhajosula S; Christos PJ; Jhanwar YS; Batra JS; Lam L; Osborne J; Beltran H; Molina AM; Goldsmith SJ; Bander NH; Nanus DM
    Cancer; 2019 Aug; 125(15):2561-2569. PubMed ID: 31012963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
    Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
    J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of short-term dexamethasone on the efficacy of
    Derlin T; Sommerlath Sohns JM; Schmuck S; Henkenberens C; von Klot CAJ; Ross TL; Bengel FM
    Prostate; 2020 May; 80(8):619-631. PubMed ID: 32187729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis.
    Rahbar K; Schmidt M; Heinzel A; Eppard E; Bode A; Yordanova A; Claesener M; Ahmadzadehfar H
    J Nucl Med; 2016 Sep; 57(9):1334-8. PubMed ID: 27056618
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):81-91. PubMed ID: 27506431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioligand Therapy With
    Yadav MP; Ballal S; Sahoo RK; Dwivedi SN; Bal C
    AJR Am J Roentgenol; 2019 Aug; 213(2):275-285. PubMed ID: 30995089
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical Outcomes of
    Barber TW; Singh A; Kulkarni HR; Niepsch K; Billah B; Baum RP
    J Nucl Med; 2019 Jul; 60(7):955-962. PubMed ID: 30683770
    [No Abstract]   [Full Text] [Related]  

  • 17. TheraP: a randomized phase 2 trial of
    Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID
    BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (
    Niaz MJ; Batra JS; Walsh RD; Ramirez-Fort MK; Vallabhajosula S; Jhanwar YS; Molina AM; Nanus DM; Osborne JR; Bander NH; Tagawa ST
    Oncologist; 2020 Jun; 25(6):477-e895. PubMed ID: 31999003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in
    Ling SW; de Blois E; Hooijman E; van der Veldt A; Brabander T
    Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer.
    Lunger L; Tauber R; Feuerecker B; Gschwend JE; Eiber M; Heck MM
    Transl Androl Urol; 2021 Oct; 10(10):3963-3971. PubMed ID: 34804839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.